{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:34:37Z","timestamp":1790854477285,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Barinthus Biotherapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clearance of high-risk oncogenic human papillomaviruses (hrHPV) and related cervical lesions is associated with the development of a robust T-cell response. Therapeutic vaccination that induces HPV antigen-specific T cells is a promising approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A 2-vector dosing strategy using Chimpanzee Adenovirus Oxford 1-HPV and Modified Vaccinia virus Ankara-HPV, both encoding the same multiantigen HPV cassette was given on a 0\/28-day schedule to participants with persistent cervical hrHPV and a history of low-grade cervical lesions. An open-label lead-in was followed by a randomized, blinded, placebo-controlled main phase. The primary endpoint was the safety of the different dose regimens; secondary endpoints included immunogenicity, and clearance of hrHPV and associated lesions at 12 months. Nine participants were enrolled in the lead-in and 99 were randomized 67:32 to 5 active dose arms or placebo, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The regimens were well-tolerated with no grade 3\u2013related treatment emergent adverse events or serious adverse reactions. All dosing regimens generated antigen-specific CD4+ and CD8+ T-cell responses. There was no difference in hrHPV clearance between the pooled active groups and placebo (20\/64 [31.3%] versus 10\/30 [33.3%]; P &amp;gt; .99), nor in lesion clearance. A trend toward higher hrHPV clearance (60%) was observed with the highest Chimpanzee Adenovirus Oxford 1-HPV doses. No association between the peripheral immune response and clearance was demonstrated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A heterologous, multiantigenic HPV 2-component immunotherapy regimen was well-tolerated and immunogenic but did not result in a statistically significant clearance of either hrHPV or the associated cervical lesions in women with persistent high-risk HPV infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EudraCT 2019-001890-98; NCT04607850<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf658","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:51:03Z","timestamp":1765284663000},"page":"51-58","source":"Crossref","is-referenced-by-count":2,"title":["A Phase 1b\/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-4720","authenticated-orcid":false,"given":"Karin","family":"Hellner","sequence":"first","affiliation":[{"name":"Nuffield Department of Women's and Reproductive Health, Oxford University , Oxford ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, HUB Hospital Erasme , Bruxelles ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"De Sutter","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, UZ Brussels , Jette ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadri-Liina","family":"Vahula","sequence":"additional","affiliation":[{"name":"P\u00e4rnu Hospital Women's and Children's Clinic , P\u00e4rnu ,","place":["Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Briggs","sequence":"additional","affiliation":[{"name":"Liverpool Women's NHS Foundation Trust , Liverpool ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dclle","family":"Kiisla","sequence":"additional","affiliation":[{"name":"North Estonia Medical Centre Foundation Surgery Clinic , Tallinn ,","place":["Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Russell","sequence":"additional","affiliation":[{"name":"Royal Victoria Infirmary , The Newcastle upon Tyne NHS hospitals foundation trust ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Newton","sequence":"additional","affiliation":[{"name":"St Michael's Hospital, Women's and Children's Research Unit , Bristol ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7454-7282","authenticated-orcid":false,"given":"Kobe","family":"Dewilde","sequence":"additional","affiliation":[{"name":"Department of Gynecology, UZ Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Anderson","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Kopycinski","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Vardeu","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Davis","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sebastian","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisha","family":"Kennerley","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4886-7257","authenticated-orcid":false,"given":"Vicky","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Jones","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dereck","family":"Tait","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3623-8059","authenticated-orcid":false,"given":"Matthew","family":"Downs","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Dorrell","sequence":"additional","affiliation":[{"name":"Nuffield Department of Women's and Reproductive Health, Oxford University , Oxford ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9072-2493","authenticated-orcid":false,"given":"Gemma","family":"Hancock","sequence":"additional","affiliation":[{"name":"Nuffield Department of Women's and Reproductive Health, Oxford University , Oxford ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-3928","authenticated-orcid":false,"given":"Kate","family":"Cuschieri","sequence":"additional","affiliation":[{"name":"Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Evans","sequence":"additional","affiliation":[{"name":"Barinthus Biotherapeutics PLC , Harwell ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2026072309024363300_ciaf658-B1","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMcp2108502","article-title":"Human papillomavirus vaccination","volume":"388","author":"Markowitz","year":"2023","journal-title":"New Engl J Med"},{"key":"2026072309024363300_ciaf658-B2","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"2026072309024363300_ciaf658-B3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"2026072309024363300_ciaf658-B4","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30 Suppl 5","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"2026072309024363300_ciaf658-B5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"2026072309024363300_ciaf658-B6","doi-asserted-by":"crossref","first-page":"101224","DOI":"10.1016\/j.mam.2023.101224","article-title":"Vaccines for HPV-associated diseases","volume":"94","author":"Skolnik","year":"2023","journal-title":"Mol Aspects Med"},{"key":"2026072309024363300_ciaf658-B7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/14737159.2014.865521","article-title":"Cobas 4800 HPV test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens","volume":"14","author":"Isidean","year":"2014","journal-title":"Expert Rev Mol Diagn"},{"key":"2026072309024363300_ciaf658-B8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12026-009-8141-6","article-title":"Therapeutic HPV DNA vaccines","volume":"47","author":"Lin","year":"2010","journal-title":"Immunol Res"},{"key":"2026072309024363300_ciaf658-B9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/GCO.0b013e32831a9890","article-title":"Host immune responses to cervical cancer","volume":"21","author":"Patel","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2026072309024363300_ciaf658-B10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1086\/315706","article-title":"Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens","volume":"182","author":"Nakagawa","year":"2000","journal-title":"J Infect Dis"},{"key":"2026072309024363300_ciaf658-B11","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6","volume":"64","author":"de Jong","year":"2004","journal-title":"Cancer Res"},{"key":"2026072309024363300_ciaf658-B12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ijc.24804","article-title":"A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses","volume":"126","author":"Woo","year":"2010","journal-title":"Int J Cancer"},{"key":"2026072309024363300_ciaf658-B13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.bjc.6602679","article-title":"T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia","volume":"93","author":"Steele","year":"2005","journal-title":"Br J Cancer"},{"key":"2026072309024363300_ciaf658-B14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00262-011-1092-5","article-title":"CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend","volume":"61","author":"Kim","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2026072309024363300_ciaf658-B15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1099\/vir.0.82678-0","article-title":"Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2","volume":"88","author":"Dillon","year":"2007","journal-title":"J General Virol"},{"key":"2026072309024363300_ciaf658-B16","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"2026072309024363300_ciaf658-B17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ygyno.2019.12.017","article-title":"Current status of therapeutic HPV vaccines","volume":"156","author":"Clark","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2026072309024363300_ciaf658-B18","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"2026072309024363300_ciaf658-B19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41541-020-00240-0","article-title":"Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans","volume":"5","author":"Capone","year":"2020","journal-title":"NPJ Vaccines"},{"key":"2026072309024363300_ciaf658-B20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jinf.2019.02.003","article-title":"Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults","volume":"78","author":"Green","year":"2019","journal-title":"J Infect"},{"key":"2026072309024363300_ciaf658-B21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","article-title":"Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)","volume":"11","author":"Mothe","year":"2019","journal-title":"EClinicalMedicine"},{"key":"2026072309024363300_ciaf658-B22","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J Infect Dis"},{"key":"2026072309024363300_ciaf658-B23","doi-asserted-by":"crossref","first-page":"e0141687","DOI":"10.1371\/journal.pone.0141687","article-title":"A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults","volume":"10","author":"Sheehan","year":"2015","journal-title":"PLoS One"},{"key":"2026072309024363300_ciaf658-B24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S\/AS01B with chimpanzee adenovirus 63 and modified vaccinia Ankara vectored vaccines expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J Infect Dis"},{"key":"2026072309024363300_ciaf658-B25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"2026072309024363300_ciaf658-B26","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3390\/vaccines9111262","article-title":"Novel antigenic targets of HPV therapeutic vaccines","volume":"9","author":"Boilesen","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2026072309024363300_ciaf658-B27","doi-asserted-by":"crossref","first-page":"18713","DOI":"10.1038\/s41598-019-55014-z","article-title":"A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins","volume":"9","author":"Hancock","year":"2019","journal-title":"Sci Rep"},{"key":"2026072309024363300_ciaf658-B28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2018.02.016","article-title":"Nanoscale artificial antigen presenting cells for cancer immunotherapy","volume":"98","author":"Rhodes","year":"2018","journal-title":"Mol Immunol"},{"key":"2026072309024363300_ciaf658-B29","doi-asserted-by":"crossref","first-page":"e115161","DOI":"10.1371\/journal.pone.0115161","article-title":"A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS","volume":"9","author":"de Barra","year":"2014","journal-title":"PLoS One"},{"key":"2026072309024363300_ciaf658-B30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026072309024363300_ciaf658-B31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discov"},{"key":"2026072309024363300_ciaf658-B32","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1080\/21645515.2020.1823778","article-title":"Durability of response to VGX-3100 treatment of HPV16\/18 positive cervical HSIL","volume":"17","author":"Bhuyan","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2026072309024363300_ciaf658-B33","doi-asserted-by":"crossref","first-page":"1652.e1","DOI":"10.1016\/j.cmi.2022.06.027","article-title":"Comparison of four assays for human papillomavirus detection in the anal canal","volume":"28","author":"Poynten","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026072309024363300_ciaf658-B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149950","article-title":"Distinct populations of antigen specific tissue resident CD8 T cells in human cervix mucosa","author":"Peng","year":"2021","journal-title":"JCI Insight"},{"key":"2026072309024363300_ciaf658-B35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/gyno.2000.5903","article-title":"Differential distribution of sequence variations in HPV-16 E6","volume":"79","author":"Gostout","year":"2000","journal-title":"Gynecol Oncol"},{"key":"2026072309024363300_ciaf658-B36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.virol.2010.10.039","article-title":"E6 molecular variants of human papillomavirus (HPV) type 16: an updated and unified criterion for clustering and nomenclature","volume":"410","author":"Huertas-Salgado","year":"2011","journal-title":"Virology"},{"key":"2026072309024363300_ciaf658-B37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/ijc.31166","article-title":"Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins","volume":"142","author":"\u00c7uburu","year":"2018","journal-title":"Int J Cancer"},{"key":"2026072309024363300_ciaf658-B38","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4049\/jimmunol.1800219","article-title":"A prime-pull-amplify vaccination strategy to maximize induction of circulating and genital-resident intraepithelial CD8+ memory T cells","volume":"202","author":"\u00c7uburu","year":"2019","journal-title":"J Immunol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf658\/65932178\/ciaf658.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/1\/51\/65932178\/ciaf658.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/1\/51\/65932178\/ciaf658.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:02:51Z","timestamp":1784811771000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/1\/51\/8382249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2026,7,23]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf658","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,15]]},"published":{"date-parts":[[2025,12,17]]}}}